CGVHD
Clinical trials for CGVHD explained in plain language.
Never miss a new study
Get alerted when new CGVHD trials appear
Sign up with your email to follow new studies for CGVHD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to tame chronic GVHD
Disease control Recruiting nowThis study tests whether combining a drug called axatilimab with a blood-filtering procedure (ECP) can help people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. About 49 participants who have tried at least two prior treatments will …
Matched conditions: CGVHD
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Arthritis drug repurposed to fight stem cell transplant complication
Disease control Recruiting nowThis phase 3 trial tests whether iguratimod, a drug already used for rheumatoid arthritis, can safely and effectively treat chronic graft-versus-host disease (cGVHD) in people who have had a stem cell transplant. The study will enroll 20 adults who have persistent cGVHD despite p…
Matched conditions: CGVHD
Phase: PHASE3 • Sponsor: Xuzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Experimental cell injection targets stubborn GVHD
Disease control Recruiting nowThis early-phase trial tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. The study will enroll 36 participants to check safety and see if the treatment can reduce symptoms. It's a first s…
Matched conditions: CGVHD
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug aims to stop immune attack after stem cell transplants
Disease control Recruiting nowThis study tests a drug called BPC2001 to prevent acute graft-versus-host disease (aGVHD), a serious complication where donor immune cells attack the patient's body after a stem cell transplant. Fifty adults with blood cancers like leukemia will receive six weekly doses of BPC200…
Matched conditions: CGVHD
Phase: PHASE2 • Sponsor: BioPhoenix Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New cell therapy aims to tame Graft-Versus-Host disease
Disease control Recruiting nowThis early-phase trial tests whether infusing specially prepared donor immune cells (Treg cells) along with low-dose interleukin-2 can safely treat refractory chronic graft-versus-host disease (cGVHD), a serious complication after stem cell transplants. The study will enroll 18 a…
Matched conditions: CGVHD
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New study tracks 1,500 transplant patients to unlock secrets of a devastating complication
Knowledge-focused Recruiting nowThis study follows 1,500 adults who recently had a stem cell transplant and are at risk for chronic Graft-Versus-Host Disease (cGVHD), a condition where donor cells attack the recipient's body. Researchers will collect data on how often cGVHD occurs, how severe it is, and what he…
Matched conditions: CGVHD
Sponsor: Incyte Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC